CEChristoph Ehlken

Christoph Ehlken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christoph Ehlken has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Böhringer

    Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Freiburg, Deutschland

    3 shared publications
  • Andreas Stahl

    Eye Center, Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Killianstraße 5, 79106, Freiburg im Breisgau, Germany

    2 shared publications
  • Constantin von Medem

    Klinik für Ophthalmologie des Universitätsklinikums Schleswig Holsteins, Kiel, Germany

    2 shared publications
  • Johann Baptist Roider

    Klinik für Ophthalmologie des Universitätsklinikums Schleswig Holsteins, Kiel, Germany

    2 shared publications
  • Maya Lüdemann

    Klinik für Ophthalmologie des Universitätsklinikums Schleswig Holsteins, Kiel, Germany

    2 shared publications
  • Nicole Eter

    Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany

    2 shared publications

Latest Publications

  • Participation in a clinical trial—Is that something for me?

    by Katrin Lorenz, Daniel Böhringer, Barbara Wilhelm, Sabine Aisenbrey, Katharina Allgeier, Isabella Baur, Eckart Bertelmann, Christian Karl Brinkmann, Lars Choritz, Christoph Deuter, et al.

    Zusammenfassung Fragestellung Die Zulassung neuer Therapien in der Augenheilkunde macht klinische Studien essenziell notwendig. Regelmäßig stellt die Rekrutierung geeigneter Studienpatienten eine große Herausforderung für die teilnehmenden Kliniken dar. Viele Patienten haben grundsätzliche Vorbehalte und Ängste gegenüber Studien, die sie von einer Teilnahme abhalten. Da diese Bedenken an allen Standorten im Land ähnlich sind, soll ihnen mit einem breit anwendbaren Video begegnet werden. Erstmalig werden darin die Aspekte einer Studienteilnahme rein aus der Patientenperspektive vermittelt. Methodik Das Konzept für das Video wurde von der AG DOG (Deutsche Ophthalmologische Gesellschaft) Klinische Studienzentren erarbeitet. An mehreren Standorten wurden Patienten für die Mitwirkung gesucht und 2 geeignete Protagonisten ausgewählt. Die Mitwirkung war freiwillig und ehrenamtlich. Die Dreharbeiten fanden in Q (Quartal) 3 und Q4 2021 in Baden-Württemberg statt. Die Produktion lag in den Händen der Agentur grasshopper kreativ, Tübingen. Ergebnis Die beiden Patienten schildern ihre eigenen Bedenken vor der Studie und wie sie die Studienteilnahme selbst erlebt haben. Dabei kommen Aspekte wie die Freiwilligkeit, das Rücktrittsrecht, Angst vor unangenehmen Untersuchungen, die zeitliche Belastung u. a. m. zur Sprache. Die Patienten gehen auch auf ihre persönliche Motivation zur Teilnahme ein. Das Video ist authentisch in seiner Wirkung, in deutscher Sprache gehalten und mit Untertiteln für Bereiche versehen, wo es ohne Ton präsentiert werden muss. Diese Untertitel sind auch in englischer Sprache verfügbar, um den Interessentenkreis auszuweiten. Schlussfolgerung Mit dem Video steht ein wichtiges Instrument zur Aufklärung von Patienten und für die Rekrutierung klinischer Studien an Augenkliniken kostenfrei zur Verfügung.


  • Open Access

    Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) for neovascular age-related macular degeneration: a cross-sectional diagnostic accuracy study

    by Claus von der Burchard, Helge Sudkamp, Jan Tode, Cristoph Ehlken, Konstantine Purtskhvanidze, Moritz Moltmann, Britta Heimes, Peter Koch, Michael Münst, Malte Vom Endt, et al.

    Objectives Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) is a novel OCT technology that was specifically designed for home monitoring of neovascular age-related macular degeneration (AMD). First clinical findings have been reported before. This trial investigates an improved prototype for patients with AMD and focusses on device operability and diagnostic accuracy compared with established spectral-domain OCT (SD-OCT). Design Prospective single-arm diagnostic accuracy study. Setting Tertiary care centre (University Eye Clinic). Participants 46 patients with age-related macular degeneration. Interventions Patients received short training in device handling and then performed multiple self-scans with the SELFF-OCT according to a predefined protocol. Additionally, all eyes were examined with standard SD-OCT, performed by medical personnel. All images were graded by at least 2 masked investigators in a reading centre. Primary outcome measure Rate of successful self-measurements. Secondary outcome measures Sensitivity and specificity of SELFF-OCT versus SD-OCT for different biomarkers and necessity for antivascular endothelial growth factor (anti-VEGF) treatment. Results In 86% of all examined eyes, OCT self-acquisition resulted in interpretable retinal OCT volume scans. In these patients, the sensitivity for detection of anti-VEGF treatment necessity was 0.94 (95% CI 0.79 to 0.99) and specificity 0.95 (95% CI 0.82 to 0.99). Conclusions SELFF-OCT was used successfully for retinal self-examination in most patients, and it could become a valuable tool for retinal home monitoring in the future. Improvements are in progress to reduce device size and to improve handling, image quality and success rates. Trial registration number DRKS00013755, CIV-17-12-022384.


  • Open Access

    Patients’ perspective on emergency treatment of ophthalmologic diseases during the first phase of SARS-CoV2 pandemic in a tertiary referral center in Germany – the COVID-DETOUR questionnaire study

    by Christoph Ehlken, Constantin von Medem, Maya Lüdemann, Anna Maria Kirsch, Johann Baptist Roider

    Background: During the first wave of the COVID-19 pandemic, the need of treatment of urgent ophthalmological diseases and the possible risk of a SARS-CoV-2 infection had to be weighed against each other. In this questionnaire study, we aimed to analyze potential barriers and patients’ health beliefs during and after the lockdown early 2020 in a tertiary referral center in Kiel, Germany.Methods: Patients admitted for the treatment of urgent ophthalmic diseases between March 1st, 2020, and June 3rd, 2020, were asked to participate in a questionnaire study. After informed consent was obtained, patients were interviewed using a standardized questionnaire which addressed aspects of their medical history, their health beliefs concerning the COVID-19 pandemic and barriers on their way to the treatment center. The study group was subdivided into two subgroups, depending on the occurrence of their symptoms, before and after the lockdown was ended on April 20th, 2020.Results: Ninety-three patients were included, 43 in subgroup A (before April 20th) and 50 in subgroup B (April 20th or later). Retinal disorders were the most common causes for admission (approximately 60%).. Only 8 patients (8.6%) experienced a delay between their decision to visit a doctor until the actual examination. Every fourth patient was afraid of a COVID-19 infection, and expected a higher likelihood for an infection at the hospital. Patients with comorbidities tended to be more likely to be afraid of an infection (correlation coefficient 0.183,p = 0.0785) and were significantly more likely to be concerned about problems with organizing follow-up care (corr. Coefficient 0.222,p = 0.0328). Higher age was negatively correlated with fear of infection (corr. Coefficient − 0.218,p-value 0.034).Conclusion: In this questionnaire study, only a minority of patients indicated a delay in treatment, regardless of whether symptoms occurred before or after the lockdown before April 20th, 2020. While patients with comorbidities were more concerned about infection and problems during follow-up care, patients of higher age – who have a higher mortality – were less afraid. Protection of high-risk groups should be prioritized during the SARS-CoV-2 pandemic.Trial registration: The study was registered asDRKS00021630at the DRKS (Deutsches Register Klinischer Studien) before the conduction of the study on May 5th, 2020.


  • Open Access

    Emergency treatment of ophthalmologic diseases during the first phase of SARS-CoV2 pandemic in a tertiary referral center in Germany – the COVID-DETOUR questionnaire study

    by Christoph Ehlken, Constantin von Medem, Maya Lüdemann, Anna Maria Barbara Kirsch, Johann Baptist Roider

    Background:During the first wave of the COVID-19 pandemic, the need of treatment of urgent ophthalmological diseases and the possible risk of a SARS-CoV-2 infection had to be weighed against each other. In this questionnaire study, we aimed to analyze potential barriers and patients’ health beliefs during and after the lockdown early 2020 in a tertiary referral center in Kiel, Germany.Methods:Patients admitted for the treatment of urgent ophthalmic diseases between March 1st, 2020, and June 3rd, 2020, were asked to participate in a questionnaire study. After informed consent was obtained, patients were interviewed using a standardized questionnaire which addressed aspects of their medical history, their health beliefs concerning the COVID-19 pandemic and barriers on their way to the treatment center. The study group was subdivided into two subgroups, depending on the occurrence of their symptoms, before and after the lockdown was ended on April 20th, 2020.Results:Ninety-three patients were included, 43 in subgroup A (before April 20th) and 50 in subgroup B (April 20th or later). Retinal disorders were most common (approximately 60%), with retinal detachments being the most singular reason for admission. Only 8 patients (8.6%) experienced a delay between their decision to visit a doctor until the actual examination. Every fourth patient was afraid of a COVID-19 infection, and expected a higher likelihood for an infection at the hospital. Patients with comorbidities tended to be more likely to be afraid of an infection (correlation coefficient 0.183, p=0.0785) and were significantly more likely to be concerned about problems with organizing follow-up care (corr. coefficient 0.222, p=0.0328). Higher age was negatively correlated with fear of infection (corr. coefficient -0.218, p-value 0.034).Conclusion:In this questionnaire study, only a minority of patients indicated a delay in treatment, regardless of whether symptoms occurred before or after the lockdown before April 20th. While patients with comorbidities were more concerned about infection and problems during follow-up care, patients of higher age – who have a higher mortality – were less afraid. Protection of high-risk groups should be prioritized during the SARS-CoV-2 pandemic.Trial registration:The study was registered as DRKS00021630 at the DRKS (Deutsches Register Klinischer Studien) before the conduction of the study on May 5th, 2020.

  • Open Access

    Systematic review: non-adherence and non-persistence in intravitreal treatment

    by Christoph Ehlken, Focke Ziemssen, Nicole Eter, Ines Lanzl, Hakan Kaymak, Albrecht Lommatzsch, Alexander K. Schuster

    Purpose: Intravitreal injection of VEGF inhibitors has become the standard of care for different macular diseases within the last years resulting in improved visual outcomes. Under real-life conditions, however, the necessity for frequent retreatments and reexaminations poses a burden for patients and treatment centers. Non-adherence and non-persistence to intravitreal treatment may lead to inferior clinical outcomes, and knowledge of contributing factors is crucial to improve adherence. This systematic review analyzes current literature for potential factors involved in non-adherence and non-persistence. Methods: A systematic search was conducted in PubMed and Embase including three different aspects of intravitreal injection therapy: (1) diseases with intravitreal injections as treatment, (2) intravitreal injection, and (3) aspects of therapy adherence or therapy persistence. Data from identified quantitative studies were further extracted and grouped according to WHO criteria (condition, socio-economy, therapy, patient, and health system). The methodological quality of identified studies was graded. Identified qualitative studies (i.e., interviews) were descriptively analyzed and their findings narratively reported. Results: Twenty-four publications were included. In 16 of those publications, a quantitative data analysis was conducted, analyzing factors associated with non-adherence. Worse visual acuity at baseline and unfavorable development of visual acuity, higher age, and greater distance to the treatment center were associated with non-adherence, while there was inconsistent evidence for an association of comorbidity. In qualitative studies, high follow-up/treatment burden, fear and anxiety, disappointed patient expectations, and lack of motivation to continue treatment were reported as reasons for non-persistence. Conclusions: Knowledge of potential barriers in IVT treatment may improve adherence and potentially clinical results. Improvements can be achieved particularly in the healthcare complex (organizational improvements) and the “patient” complex by establishing realistic expectations. Recurrent education of the patient may be necessary.


  • Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies

    by Marie-Christine Bruender, Nicola Benjamin, Hansjuergen Thomas Agostini, Andreas Stahl, Christoph Ehlken

    Patients with exudative maculopathies (neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)) are faced with a high burden of examinations and treatments. This study was conceived to analyze the accuracy of a subjective evaluation of visual acuity (VA) and metamorphopsia to detect disease reactivation, compared to morphological signs of reactivation assessed by means of SD-OCT.


  • Open Access

    Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients

    by Christoph Ehlken, Mandy Helms, Daniel Böhringer, Hansjürgen T Agostini, Andreas Stahl

    Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients Christoph Ehlken,1,2 Mandy Helms,1 Daniel Böhringer,1 Hansjürgen T Agostini,1 Andreas Stahl1 1Ophthalmology, Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, 2Ophthalmology, Eye Center, University Hospital Schleswig-Holstein, Campus Kiel, Germany Purpose: Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular edema secondary to branch retinal vein occlusion (BRVO) are often inferior to results from randomized clinical trials. This observational cohort study investigates treatment adherence and real-life clinical outcomes within the first year of treatment.Patients and methods: A total of 708 treatment-naïve patients (466 nAMD, 134 DME, and 108 BRVO) were included. Patients were followed with a PRN treatment protocol with three intravitreal injections (IVIs) and a series of 3 monthly injections in case of persistent or recurrent disease activity, as determined by monthly follow-up exams including optical coherence tomographies. Occurrence of gaps of >56 days between treatments or follow-up (nonadherence [NA]) and the reasons for NA (patient- or center-associated) as well as disease activity within the first 12 months of treatment were analyzed. Visual acuity (VA) as well as numbers and dates of optical coherence tomography and IVI were extracted from medical records.Results: NA occurred significantly more often in patients with DME (44%) than nAMD (32%) or BRVO (25%, p<0.01 between groups). NA was mainly patient-associated (nAMD: 80.0%, DME: 83.1%, BRVO: 70.4%, p=0.38 between groups). Patients with nAMD and DME and appropriate treatment/follow-up adherence had a better chance of significantly gaining or maintaining VA, respectively (19.9% vs 12.0% with 3-line-gain in nAMD and 1.3% vs 15.3% 3-line loss in DME; each p0.05).Conclusion: NA to treatment and follow-up regimens is a common problem in the management of patients with AMD and DME and limits clinical treatment outcomes under real-life conditions. Patients with DME have the highest risk of patient-associated NA, associated with a higher risk for significant VA loss. Keywords: AMD, RVO, DME, adherence, anti-VEGF, PRN, follow-up


  • Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD

    by Christoph Ehlken, Daniel Böhringer, Hansjürgen T. Agostini, Bastian Grundel, Milena Stech

    Stereotactic radiotherapy (SRT, IRay) was able to reduce the need for intravitreal injections of anti-VEGF (IVI) in patients with neovascular AMD (nAMD) in a phase II randomized clinical trial. Certain morphologic characteristics, such as lesion size < 4 mm2 or lack of fibrosis, were associated with a better response. The purpose of this cross-sectional study was to investigate eligibility for SRT in a clinical routine setting and to compare clinical features of eligible and non-eligible patients.


  • Expression of Angiogenic and Inflammatory Factors in Choroidal Neovascularisation-Derived Retinal Pigment Epithelium

    by Christoph Ehlken, Maria-Magdalena Guichard, Günther Schlunck, Anima D. Bühler, Gottfried Martin, Hansjürgen T. Agostini

    Purpose: Anti-angiogenic treatment is well established in the management of exudative age-related macular degeneration (AMD), but not sufficient in all patients. The characterisation of factors driving this chronic disease could serve to identify additional treatment options. The purpose of this study was to assess gene expression patterns and distinct changes in cells derived from surgically extracted choroidal neovascularisation (CNV) membranes. Materials and Methods: The expression of >11,000 genes was analysed by means of a microarray in cells cultured from 2 late-stage CNV membranes compared to primary human retinal pigment epithelium (RPE) and ARPE-19 cells. A pathway analysis was performed to identify gene expression patterns associated with exudative AMD. Results: The analysis revealed significant alterations in gene sets associated with inflammatory processes in CNV-derived cells, involving the upregulation of pro-inflammatory factors IL6, C3, and C5, and downregulation of anti-inflammatory complement factor B and complement factor I. Factors associated with angiogenesis, such as VEGFA or ANGPT2, were not significantly regulated in the 2 RPE-derived cell lines. Conclusion: In late-stage CNV membrane-derived RPE, gene expression was shifted towards a pro-inflammatory state. Angiogenesis-associated factors were regulated differently in the 2 CNV-derived RPE membranes. While inflammation seems to be continuously stimulated by RPE associated with late exudative AMD, this appears not to be the case with regard to angioregulatory mechanisms.